Search

Your search keyword '"Barlow, L."' showing total 241 results
Start Over Author "Barlow, L." Publication Year Range Last 50 years
241 results on '"Barlow, L."'

4. P378 The value of a community of practice, within the CFHealthHub learning health system

Author

Daniels, T., primary, Hutchings, M., additional, Dawson, S., additional, Farrell, S., additional, Sandler, R.D., additional, Cameron, S., additional, Lai, L.Y., additional, Choyce, J., additional, Pickering, N., additional, Dooney, M., additional, Pilkington, E., additional, Dowdell, C., additional, Morgan, H., additional, Anderson, A., additional, Galey, P., additional, Warnock, L., additional, Barnett, T., additional, Thomas, M., additional, Gledhill, H., additional, Dale, W., additional, Barlow, L., additional, Ballinger, K., additional, Lee, K., additional, Robson, N., additional, Hoo, Z.H., additional, and Wildman, M.J., additional

Published
2023
Full Text
View/download PDF

5. P147 “What options are available for those not able to take current CFTR modulators?”: an answer hidden in plain sight?

Author

Daniels, T., primary, Lai, L.Y., additional, Cameron, S., additional, Dawson, S., additional, Farrell, S., additional, Hutchings, M., additional, Sandler, R.D., additional, Whitehouse, J., additional, Withers, N., additional, Baker, L., additional, Bourke, S.J., additional, Dooney, M., additional, Saba, T., additional, Pasteur, M., additional, Waine, D., additional, Derry, D., additional, Allenby, M., additional, Bateman, K., additional, Pilkington, E., additional, Warnock, L., additional, Gledhill, H., additional, Chapman, S., additional, Galey, P., additional, Choyce, J., additional, Pickering, N., additional, Dewar, J., additional, Fitch, G., additional, McGowan, A., additional, Thomas, R., additional, Shiferaw, D., additional, Dowdell, C., additional, Morgan, H., additional, Anderson, A., additional, Barnett, T., additional, Thomas, M., additional, Dale, W., additional, Barlow, L., additional, Ballinger, K., additional, Lee, K., additional, Robson, N., additional, Wildman, M.J., additional, and Hoo, Z.H., additional

Published
2023
Full Text
View/download PDF

12. Abstracts of the 6th FECS Conference 1998 Lectures

Author

Rowland, F. Sherwood, Blake, Donald R., Larsen, B. R., Lindskog, Anne, Peterson, Peter J., Williams, W. Peter, Wallington, T. J., Pilling, M. J., Carslaw, N., Creasey, D. J., Heard, D. E., Jacobs, P., Lee, J., Lewis, A. C., McQuaid, J. B., Stockwell, William R., Frank, Hartmut, Sacco, P., Cocheo, V., Lynge, E., Andersen, A., Nilsson, R., Barlow, L., Pukkala, E., Nordlinder, R., Boffetta, P., Grandjean, P., Heikkil, P., Hürte, L. G., Jakobsson, R., Lundberg, I., Moen, B., Partanen, T., Riise, T., Borowiak, A., De Saeger, E., Schnitzler, K. G., Gravenhorst, G., Jacobi, H. W., Moelders, S., Lammel, G., Busch, G., Beese, F. O., Dentener, F. J., Feichter, J., Fraedrich, K., Roelofs, G. J., Friedrich, R., Reis, S., Voehringer, F., Simpson, D., Moussiopoulos, N., Sahm, P., Tourlou, P. M., Salmons, R., Papameletiou, D., Maqueda, J. M., Suhr, Per B., Bell, W., Paton-Walsh, C., Woods, P. T., Partridge, R. H., Slemr, J., Slemr, F., Schmidbauer, N., Ravishankara, A. R., Jenkin, Michael E., de Leeuw, G., van Eijk, A. M. J., Flossmann, A. I., Wobrock, W., Mestayer, P. G., Tranchant, B., Ljungström, E., Karlsson, R., Larsen, S. E., Roemer, M., Builtjes, P. J. H., Koffi, Brigitte, Koffi, Ernest N’Dri, De Saeger, Emile, Ro-Poulsen, H., Mikkelsen, T. N., Hummelshøj, P., Hovmand, M. F., Simoneit, Bernd R. T., van der Meulen, A., Meyer, Michael B., Berndt, T., Böge, O., Stratmann, F., Cass, Glen R., Harrison, Roy M., Shi, Ji Ping, Hoffmann, T., Warscheid, B., Bandur, R., Marggraf, U., Nigge, W., Kamens, Richard, Jang, Myoseon, Strommen, Mike, Chien, Chao-Jung, Leach, Keri, Ammann, M., Kalberer, M., Arens, F., Lavanchy, V., Gâggeler, H. W., Baltensperger, U., Davies, J. A., Cox, R. A., Alonso, S. García, Pastor, R. Pérez, Argüello, Gustavo A., Willner, Helge, Berndt, T., Böge, O., Bogillo, V. I., Pokrovskiy, V. A., Kuraev, O. V., Gozhyk, P. F., Bolzacchini, E., Bruschi, M., Fantucci, P., Meinardi, S., Orlandi, M., Rindone, B., Bolzacchini, Ezio, Bohn, Birger, Rindone, Bruno, Bruschi, Maurizo, Zetzsch, Cornelius, Brussol, C., Duane, M., Larsen, B., Carlier, P., Kotzias, D., Caracena, A. Baeza, Aznar, A. Miñana, Ferradás, E. González, Christensen, C. S., Skov, H., Hummelshøj, P., Jensen, N. O., Lohse, C., Cocheo, V., Sacco, P., Chatzis, C., Cocheo, V., Sacco, P., Boaretto, C., Quaglio, F., Zaratin, L., Pagani, D., Cocheo, L., Cocheo, Vincenzo, Asnar, Agustin Minana, Baldan, Annerita, Ballesta, Pascual P., Boaretto, Caterina, Caracena, Antonia B., Ferradas, Enrique Gonzalez, Gonzalez-Flesca, Nobert, Goelen, Eddie, Hansen, Asger B., Sacco, Paolo, De Saeger, Emile, Skov, Henrik, Consonni, V., Gramatica, P., Santagostino, A., Galvani, P., Bolzacchini, E., Consonni, Viviana, Gramatica, Paola, Todeschini, Roberto, Dippel, G., Reinhardt, H., Zellner, R., Dämmer, K., Bednarek, G., Breil, M., Zellner, R., Febo, A., Allegrini, I., Giliberti, C., Perrino, C., Fogg, P. G. T., Geiger, H., Barnes, I., Becker, K. H., Maurer, T., Geyskens, F., Bormans, R., Lambrechts, M., Goelen, E., Giese, Martina, Frank, Hartmut, Glasius, M., Hornung, P., Jacobsen, J. K., Klausen, H. S., Klitgaard, K. C., Møller, C. K., Petersen, A. P. F., Petersen, L. S., Wessel, S., Hansen, T. S., Lohse, C., Boaretto, E., Heinemeier, J., Glasius, M., Di Bella, D., Lahaniati, M., Calogirou, A., Jensen, N. R., Hjorth, J., Kotzias, D., Larsen, B. R., Gonzalez-Flesca, N., Cicolella, A., Bates, M., Bastin, E., Gurbanov, M. A., Akhmedly, K. M., Balayev, V. S., Haselmann, K. F., Ketola, R., Laturnus, F., Lauritsen, F. R., Grøn, C., Herrmann, H., Ervens, B., Reese, A., Umschlag, Th., Wicktor, F., Zellner, R., Herrmann, H., Umschlag, Th., Müller, K., Bolzacchini, E., Meinardi, S., Rindone, B., Jenkin, Michael E., Hayman, Garry D., Jensen, N. O., Courtney, M., Hummelshøj, P., Christensen, C. S., Larsen, B. R., Johnson, Matthew S., Hegelund, Flemming, Nelander, Bengt, Kirchner, Frank, Klotz, B., Barnes, Ian, Sørensen, S., Becker, K. H., Etzkorn, T., Platt, U., Wirtz, K., Martín-Reviejo, M., Laturnus, Frank, Martinez, E., Cabañas, B., Aranda, A., Martín, P., Salgado, S., Rodriguez, D., Masclet, P., Jaffrezo, J. L., Hillamo, R., Mellouki, A., Le Calvé, S., Le Bras, G., Moriarty, J., O’Donnell, S., Wenger, J., Sidebottom, H., Mingarrol, M. T. Bomboi, Cosin, S., Pastor, R. Pérez, Alonso, S. García, Sanz, M. J., Bravo, I., Gonzalez, D., Pérez, M. A., Mustafaev, Islam, Mammadova, Saida, Noda, J., Hallquist, M., Langer, S., Ljungström, E., Nohara, K., Kutsuna, S., Ibusuki, T., Oehme, Michael, Kölliker, Stephan, Brombacher, Stephan, Merz, Leo, Pastor, R. Pérez, Alonso, S. García, Cabezas, A. Quejido, Peeters, J., Vereecken, L., El Yazal, J., Pfeffer, Hans-Ulrich, Breuer, Ludger, Platz, J., Nielsen, O. J., Sehested, J., Wallington, T. J., Ball, J. C., Hurley, M. D., Straccia, A. M., Schneider, W. F., Pérez-Casany, M. P., Nebot-Gil, I., Sánchez-Marín, J., Putz, E., Folberth, G., Pfister, G., Weissflog, L., Elansky, N. P., Sørensen, Søren, Barnes, Ian, Becker, K. H., Shao, M., Heiden, A. C., Kley, D., Rockel, P., Wildt, J., Silva, G. V. A., Vasconcelos, M. T., Fernandes, E. O., Santos, A. M. S., Skov, Henrik, Hansen, Asger, Løfstrøm, Per, Lorenzen, Gitte, Stabel, J. R., Wolkoff, P., Pedersen, T., Strom, A. B., Skov, Henrik, Hertel, Ole, Jensen, Finn Palmgren, Hjorth, Jens, Galle, Bosse, Wallin, Svante, Theloke, J., Libuda, H. G., Zabel, F., Touaty, Muriel, Bonsang, Bernard, Ullerstam, M., Langer, S., Ljungström, E., Wenger, John, Bonard, Amélie, Manning, Marcus, Nolan, Sinéad, O’Sullivan, Niamh, Sidebottom, Howard, Wenger, John, Collins, Eoin, Moriarty, Jennie, O’Donnell, Sinéad, Sidebottom, Howard, Wenger, John, Collins, Eoin, Moriarty, Jennie, O’Donnell, Sinéad, Sidebottom, Howard, Wenger, John, Sidebottom, Howard, Chadwick, Paul, O’Leary, Barbara, Treacy, Jack, Wolkoff, Peder, Clausen, Per A., Wilkins, Cornelius K., Hougaard, Karin S., Nielsen, Gunnar D., Zilinskis, Viktors, Jansons, Guntis, Peksens, Aigars, Lazdins, Agris, Arinci, Y. V., Erdöl, N., Ekinci, E., Okutan, H., Manlafalioglu, I., Bakeas, Evangelos B., Siskos, Panayotis A., Viras, Loizos G., Smirnioudi, Vasiliki N., Bottenheim, Jan W., Biesenthal, Thomas, Gong, Wanmin, Makar, Paul, Delmas, Véronique, Menard, Tamara, Tatry, Véronique, Moussafir, Jacques, Thomas, Dominique, Coppalle, Alexis, Ellermann, Thomas, Hertel, Ole, Skov, Henrik, Frohn, Lise, Manscher, Ole H., Friis, Jørgen, Girgzdiene, Rasa, Girgzdys, Aloyzas, Gurevich, N. A., Gårdfeldt, Katarina, Langer, Sarka, Hermans, C., Vandaele, A. C., Carleer, M., Fally, S., Colin, R., Bernath, P. F., Jenouvrier, A., Coquart, B., Mérienne, M. -F., Hertel, Ole, Frohn, Lise, Skov, Henrik, Ellermann, Thomas, Huntrieser, H., Schlager, H., Feigl, C., Kemp, Kåre, Palmgren, Finn, Kiilsholm, Sissi, Rasmussen, Alix, Sørensen, Jens Havskov, Klemm, Otto, Lange, Holger, Larsen, René Wugt, Larsen, Niels Wessel, Nicolaisen, Flemming, Sørensen, Georg Ole, Beukes, Jon Are, Larsen, Poul Bo, Jensen, Steen Solvang, Fenger, Jes, de Leeuw, Gerrit, Kunz, Gerard, Cohen, Leo, Schlünzen, Heinke, Muller, Frank, Schulz, Michael, Tamm, Susanne, Geernaert, Gary, Hertel, Ole, Pedersen, Britta, Geernaert, Lise Lotte Sørensen, Lund, Søren, Vignati, Elisabetta, Jickells, Tim, Spokes, Lucinda, Matei, C., Jinga, O. A., Jinga, D. C., Moliner, R., Braekman-Danheux, C., Fontana, A., Suelves, I., Thieman, T., Vassilev, S., Skov, Henrik, Hertel, Ole, Zlatev, Zahari, Brandt, Jørgen, Bastrup-Birk, Annemarie, Ellermann, Thomas, Frohn, Lise, Vandaele, A. C., Hermans, C., Carleer, M., Tsouli, A., Colin, R., Windsperger, Andreas M., Turi, Kristina, Dworak, Oliver, Zellweger, C., Weingartner, E., Rüttimann, R., Hofer, P., Baltensperger, U., Ziv, A., Iakovleva, E., Palmgren, F., Berkovicz, R., Skov, H., Alastuey, A., Querol, X., Chaves, A., Lopez-Soler, A., Ruiz, C., Andrees, J. M., Allegrini, I., Febo, A., Giusto, M., Angeloni, M., Di Filippo, P., D’Innocenzio, F., Lepore, L., Marconi, A., Arshinov, M. Yu., Belan, B. D., Davydov, D. K., Kovaleskii, V. K., Plotinov, A. P., Pokrovskii, E. V., Sklyadneva, T. K., Tolmachev, G. N., Arshinov, M. Yu., Belan, B. D., Sklyadneva, T. K., Behnke, Wolfgang, Elend, Manfred, Krüger, Ulrich, Zetzsch, Cornelius, Belan, B. D., Arshinov, M. Yu., Davydov, D. K., Kovalevskii, V. K., Plotnikov, A. P., Pokrovskii, E. V., Rasskazchikova, T. M., Sklyadneva, T. K., Tolmachev, G. N., Belan, B. D., Arshinov, M. Yu., Simonenkov, D. V., Tolmachev, G. N., Bilde, Merete, Aker, Pamela M., Börensen, C., Kirchner, U., Scheer, V., Vogt, R., Ellermann, T., Geernaert, L. L. S., Pryor, S. C., Barthelmie, R. J., Feilberg, Anders, Nielsen, Torben, Kamens, Richard M., Freitas, M. C., Marques, A. P., Reis, M. A., Alves, L. C., Ilyinskikh, N. N., Ilyinskikh, I. N., Ilyinskikh, E. N., Johansen, Keld, Stavnsbjerg, Peter, Gabrielsson, Pär, Bak, Flemming, Andersen, Erik, Autrup, Herman, Kamens, Richard, Jang, Myoseon, Strommen, Michael, Leach, Keri, Kirchner, U., Scheer, V., Börensen, C., Vogt, R., Igor, Komov, Svjatoslav, Galiy, Anatoliy, Burlak, Komov, I. L., Istchenko, A. A., Lourenço, M. G., MacTavish, D., Sirois, A., Masclet, Pierre, Jaffrezo, Jean Luc, van der Meulen, A., Milukaite, A., Morkunas, V., Jurgutis, P., Mikelinskiene, A., Nielsen, Torben, Feilberg, Anders, Binderup, Mona Lise, Pineda, M., Palacios, J. M., Garcia, E., Cilleruelo, C., Moliner, R., Popovitcheva, O. B., Trukhin, M. E., Persiantseva, N. M., Buriko, Yu, Starik, A. M., Demirdjian, B., Suzanne, J., Probst, T. U., Rietz, B., Alfassi, Z. B., Pokrovskiy, V. A., Zenobi, R., Bogatyr’ov, V. M., Gun’ko, V. M., Querol, X., Alastuey, A., Lopez-Soler, A., Mantilla, E., Plana, F., Artiño, B., Rauterberg-Wulff, A., Israël, G. W., Rocha, Teresa A. P., Duarte, Armando C., Röhrl, Andreas, Lammel, Gerhard, Spindler, G., Müller, K., Herrmann, H., Strommen, Michael R., Vignati, Elisabetta, de Leeuw, Gerrit, and Berkowicz, Ruwim

Published
1998
Full Text
View/download PDF

14. Potential Prognostic Markers for Survival and Neurologic Death in Patients with Breast Cancer Brain Metastases who Receive upfront SRS Alone

Author

Shenker, R.F., primary, Hughes, R.T., additional, McTyre, E., additional, Lanier, C.M., additional, Lo, H.W., additional, Metheny-Barlow, L., additional, Thomas, A., additional, Brown, D.R., additional, Avery, T., additional, Pasche, B., additional, Cramer, C.K., additional, Tatter, S.B., additional, Laxton, A., additional, Watabe, K., additional, and Chan, M.D., additional

Published
2018
Full Text
View/download PDF

15. Determination of Tumor Gene Expression in Non–small Cell Lung Cancer Patients Who Develop Brain Metastasis Diagnosis: Analysis of a Prospective Trial

Author

Dohm, A.E., primary, Su, J., additional, McTyre, E., additional, Soike, M., additional, Miller, L.D., additional, Petty, W.J., additional, Xing, F., additional, Lo, H.W., additional, Metheny-Barlow, L., additional, Watabe, K., additional, Chan, M.D., additional, Ruiz, J., additional, and Pasche, B., additional

Published
2017
Full Text
View/download PDF

16. Consensus statement on the use of gadolinium for magnetic resonance imaging (MRI) used in the diagnosis and follow-up of patients with multiple sclerosis (MS)

Author

Traboulsee, A., primary, Oh, J., additional, Barlow, L., additional, Chan, J., additional, Cohen, B., additional, Costello, K., additional, Halper, J., additional, Harris, C., additional, Jones, D., additional, Kanal, E., additional, Li, D., additional, Maravilla, K., additional, Nelson, F., additional, Newsome, S., additional, Pelletier, D., additional, Rammohan, K., additional, Reich, D., additional, Rovira, A., additional, Stone, L., additional, and Wolinsky, J., additional

Published
2017
Full Text
View/download PDF

18. Childhood cancer survival in Europe

Author

Gatta, G., Corazziari, I., Magnani, C., Peris Bonet, R., Roazzi, P., Stiller, C., Oberaigner, W., Jechova, M., Rousarova, M., Storm, H. H., Aareleid, T., Hakulinen, T., Hédelin, G., Tron, I., Le Gall, E., Launoy, G., Macé Lesech, I., Faivre, I., Chaplain, G., Carli, P. M., Lacour, B., Raverdy, N., Berger, C., Freycon, F., Grosclaude, P., Estève, I., Kaatsch, P., Tryggvadottir, L., Berrino, F., Allemani, C., Baili, P., Ciccolallo, L., Micheli, A., Sant, M., Taussig, E., Capocaccia, R., Carrani, E., De Angelis, R., Hartley, S., Santaquilani, M., Tavilla, A., Valente, F., Verdecchia, A., Ferretti, S., Crosignani, P., Tagliabue, G., Conti, E., Vercelli, M., Pannelli, F., Mosciatti, P., Federico, Massimo, Artioli, M. E., De Lisi, V., Serventi, L., Pastore, G., Gafà, L., Tumino, R., Falcini, F., Budroni, M., Paci, E., Crocetti, E., Zambon, P., Guzzinati, S., Dalmas, M., Langmark, F., Andersen, A, Rachtan, J., Bielska Lasota, M., Wronkowski, Z., Zwierko, M., Pleško, I., Obsitníková, A., Pompe Kirn, V., Izarzugaza, I., Martinez Garcia, C., Garau, I., Navarro, C., Chirlaque, M. D., Ardanaz, E., Moreno, C., Galceran, J., Torrella, A., Barlow, L., Möller, T., Lutz, J. M., Usel, M., Coebergh, J. W. W., Van Der Does Van Den Berg, A., Visser, O., Coleman, M. P., Black, R., and Brewster, D.

Subjects
Male, Pediatrics, medicine.medical_specialty, Adolescent, Population, Disease, Malignancy, Childhood Cancer Survival Trends, Neoplasms, medicine, Humans, Child, education, education.field_of_study, business.industry, Incidence (epidemiology), Gold standard, Age Factors, Cancer, Hematology, medicine.disease, Survival Analysis, Childhood tumours, Europe, Population-based study, Survival variation, Lymphoma, Europe, Survival Rate, Oncology, Child, Preschool, Female, Major Diagnostic Category, business
Abstract

BACKGROUND: EUROCARE-3 collected data from 45 population-based cancer registries in 20 countries on 24 620 European children aged from 0 to 14 years diagnosed with malignancy in the period 1990-1994. METHODS: Five-year survival between countries was compared for all malignancies and for the major diagnostic categories, adjusting for age, and estimated average European survival weighting for differences in childhood populations. RESULTS: For all cancers combined, survival variation was large (45% in Estonia to 90% in Iceland), and was generally low (60-70%) in eastern Europe and high (> or =75%) in Switzerland, Germany and the Nordic countries (except Denmark). The Nordic countries had the highest survival for four of the seven major tumour types: nephroblastoma (92%), acute lymphoid leukaemia (85%), CNS tumours (73%) and acute non-lymphocytic leukaemia (62%). The eastern countries had lowest survival: 89% for Hodgkin's disease, 71% for nephroblastoma, 68% for acute lymphoid leukaemia, 61% for non-Hodgkin's lymphoma, 57% for central nervous system (CNS) tumours and 29% for acute non-lymphocytic leukaemia. CONCLUSIONS: The Nordic countries represent a survival gold standard to which other countries can aspire. Since most childhood cancers respond well to treatment, survival differences are attributable to differences in access (including referral and timely diagnosis) and use of modern treatments; however, the obstacles to access and application of standard treatments probably vary markedly with country.

Published
2003
Full Text
View/download PDF

19. EUROCARE-3: survival of cancer patients diagnosed 1990–94—results and commentary

Author

Sant, M., Aareleid, T., Berrino, F., Bielska Lasota, M., Carli, P. M., Faivre, J., Grosclaude, P., Hédelin, G., Matsuda, T., Møller, H., Möller, T., Verdecchia, A., Capocaccia, R., Gatta, G., Micheli, A., Santaquilani, M., Roazzi, P., Lisi, D., Oberaigner, W., Jechova, M., Rousarova, M., Storm, H. H., Hakulinen, T., Tron, I., Le Gall, E., Launoy, G., Macé Lesech, J., Chaplain, G., Danzon, A., Tretarre, B., Colonna, M., Lacour, B., Raverdy, N., Berger, C., Freycon, F., Estève, J., Kaatsch, P., Ziegler, H., Hölzel, D., Schubert Fritschle, G., Tryggvadottir, L., Allemani, C., Baili, P., Ciccolallo, L., Taussig, E., Carrani, E., De Angelis, R., Hartley, S., Tavilla, A., Valente, F., Ferretti, S., Crosignani, P., Contiero, P., Conti, E., Vercelli, M., Pannelli, F., Vitarelli, S., Mosciatti, P., Federico, Massimo, Artioli, M. E., PONZ DE LEON, Maurizio, Benatti, Piero, De Lisi, V., Serventi, L., Zanetti, R., Patriarca, S., Magnani, C., Pastore, G., Gafà, Aw, L., Tumino, R., Falcini, F., Budroni, M., Paci, E., Crocetti, E., Zambon, P., Guzzinati, S., Dalmas, M., Langmak, F., Andersen, A., Rachtan, J., Wronkowski, Z., Zwierko, M., Pinheiro, P. S., Pleško, I., Obsitníková, A., Pompe Kirn, V., Izarzugaza, I., Martinez Garcia, C., Garau, I., Navarro, C., Chirlaque, M. D., Ardanaz, E., Moreno, C., Galceran, J., Torrella, A., Peris Bonet, R., Barlow, L., Jundt, G., Lutz, J. M., Usel, M., Coebergr, J. W. W., Van Der Does Van Den Berg, A., Visser, O., Godward, S., Coleman, M. P., Williams, E. M. I., Forman, D., Quinn, M. J., Roche, M., Edwards, S., Stiller, C., Verne, J., Bell, J., Botha, J. L., Lawrence, G., Black, R., Brewster, D., and Steward, J. A.

Subjects
Male, Urologic Neoplasms, medicine.medical_specialty, Lung Neoplasms, Skin Neoplasms, Genital Neoplasms, Female, Breast Neoplasms, Digestive System Neoplasms, Sex Factors, Case mix index, Testicular Neoplasms, Neoplasms, Internal medicine, Epidemiology, medicine, Humans, Registries, Thyroid Neoplasms, cancer survival, Survival rate, Testicular cancer, Survival analysis, Brain Neoplasms, business.industry, Prostatic Neoplasms, Cancer, Hematology, medicine.disease, Survival Analysis, Age-standardised relative survival, Cancer survival, Europe, International comparison, Population-based cancer registries, Lymphoma, Surgery, Europe, Survival Rate, Oncology, Head and Neck Neoplasms, Hematologic Neoplasms, Female, business
Abstract

EUROCARE-3 analysed the survival of 1815584 adult cancer patients diagnosed from 1990 to 1994 in 22 European countries. The results are reported in tables, one per cancer site, coded according to the International Classification of Diseases (ICD)-9 classification. The main findings of the tables are summarised and commented on in this article. For most solid cancers, wide differences in survival between different European populations were found, as also reported by EUROCARE-1 and EUROCARE-2, despite a remarkable (10%) overall increase in cancer survival from 1985 to 1994. Survival was highest in northern Europe (Sweden, Norway, Finland and Iceland), and fairly good in central-southern Europe (France, Switzerland, Austria and Spain). Survival was particularly low in eastern Europe, low in Denmark and the UK, and fairly low in Portugal and Malta. The mix of tumour stage at diagnosis explains much of the survival differences for cancers of the digestive tract, female reproductive system, breast, thyroid, and also skin melanoma. For tumours of the urinary tract and prostate, the differences were explained mainly by differences in diagnostic criteria and procedures. The case mix by anatomic subsite largely explains differences in survival for head and neck cancers. For oesophagus, pancreas, liver and brain cancer, with poor prognoses, survival differences were limited. Tumours, for which highly effective treatments are available, such as testicular cancer, Hodgkin's lymphoma and some haematological malignancies, had fairly uniform survival across Europe. Survival for all tumours combined (an indicator of the overall cancer care performance of a nation's health system) was better in young than old patients, and better in women than men. The affluence of countries influenced overall cancer survival through the availability of adequate diagnostic and treatment procedures, and screening programmes.

Published
2003
Full Text
View/download PDF

20. EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century

Author

Coleman, M. P., Gatta, G., Verdecchia, A., Estève, J., Sant, M., Storm, H., Allemani, C., Ciccolallo, L., Santaquilani, M., Berrino, F., Oberaigner, W., Jechova, M., Rousarova, M., Storm, H. H., Aareleid, T., Hakulinen, T., Hédelin, G., Tron, I., Le Gall, E., Launoy, G., Macé Lesec'h, J., Faivre, J., Chaplain, G., Carl, P. M., Danzon, A., Tretarre, B., Colonna, M., Lacour, B., Raverdy, N., Berger, C., Freycon, F., Grosclaude, P., Estèv, Z, Kaatsch, P., Ziegler, H., Hölzel, D., Schubert Fritschle, G., Tryggvadottir, L., Baili, P., Micheli, A., Taussig, E., Capocaccia, R., Carrani, E., De Angelis, R., Hartley, S., Roazzi, P., Tavilla, A., Valente, F., Ferretti, S., Crosignani, P., Contiero, P., Conti, E., Vercelli, M., Pannelli, F., Vitarelli, S., Mosciatti, P., Federico, Massimo, Artioli, M. E., PONZ DE LEON, Maurizio, Benatti, Piero, De Lisi, V., Serventi, L., Zanetti, R., Patriarca, S., Magnani, C., Pastore, G., Gafà, L., Tumino, R., Falcini, F., Budroni, M., Paci, E., Crocetti, E., Zambon, P. Guzzinati S., Dalmas, M., Langmark, F., Andersen, A., Rachtan, J., Bielska Lasota, M., Wronkowski, Z., Zwierko, M., Pinheiro, P. S., Pleško, I., Obsitníková, A., Pompe Kirn, V., Izarzugaza, I., Martinez Garcia, C., Garau, I., Navarro, C., Chirlaque, M. D., Ardanaz, E., Moreno, C., Galceran, J., Torrella, A., Peris Bonet, R., Barlow, L., Möller, T., Jundt, G. Lutz J. M., Usel, M., Coebergh, J. W. W., Van Der Does Van Den Berg, A., Visser, O., Godward, S., Williams, E. M. I., Forman, D., Quinn, M. J., Roche, M., Edwards, S., Stiller, C., Verne, J., Møller, H., Bell, J., Botha, J. L., Lawrence, G., Black, R., Brewster, D., Steward, J. A., Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Male, [SDV.OT]Life Sciences [q-bio]/Other [q-bio.OT], Pathology, medicine.medical_specialty, population-based cancer registries, Lung Neoplasms, Skin Neoplasms, Population, Uterine Cervical Neoplasms, Breast Neoplasms, Disease, Sex Factors, Testicular Neoplasms, Stomach Neoplasms, Neoplasms, Epidemiology, Health care, Humans, Medicine, Registries, cancer survival, Child, education, Survival rate, Survival analysis, education.field_of_study, business.industry, Age Factors, international comparison, Prostatic Neoplasms, Cancer, Hematology, medicine.disease, Survival Analysis, Cancer survival, Europe, Survival Rate, Oncology, Colonic Neoplasms, Female, Observational study, business, Demography
Abstract

Summary International differences and trends in cancer survival withinEurope are larger than can reasonably be accounted for by arte-fact, bias or chance. The geographical patterns and trends in sur-vival are often broadly consistent with geographical differences ortrends in the type of cancer, diagnostic investigations or overallinvestment in health care, and for several major cancers, support-ing evidence is available from population-based studies of clinicalinformation. Incomplete ascertainment of cancer cases, particu-larly of long-term survivors, may contribute to some regional andinternational differences in survival, however, and more system-atic information on completeness is required. We may concludethat large international differences in survival do exist for manycancers, but we should be cautious in drawing quantitative orcausal conclusions from observational survival data.We do not yet have a fully satisfactory interpretation of thesedifferences, but we have few alternatives to this type of study if weare to understand the determinants of improved outcome for allcancer patients, and to enable better planning of their health care.The EUROCARE Working Group has developed several strategiesto disentangle the various possible explanations [73]. These includefurther development of high-resolution studies to examine theimpact on survival differences of disease stage, staging techniquesand treatment; and further development of mathematical modelsof cure. Extension of systematic international survival compari-sons to other regions of the world, such as Australia, Canada, Japanand the USA, is also in progress (the CONCORD study) [22].Oncologists and epidemiologists may provide insight into thegeographic differences and trends in survival reported by thisstudy, and may suggest further lines of enquiry. Do we need morerefined studies of survival to monitor progress against cancer andto plan future cancer care? Will such analyses help us quantify theeffect of new treatments arising from recent progress in the basicsciences and genomics on population cancer survival rates? Sub-stantial human and financial resources are required to improve theoutcome of cancer treatment. Will future investments in cancerservices include matching investment to monitor their impact onsurvival and mortality?Earlier diagnosis and prompt, universal access to optimal treat-ment would be expected to reduce international differences incancer survival in Europe. To achieve this, oncologists and healthcare planners will need better information on the comparativeperformance of their health systems. Population-based cancer reg-istries provide some of the information for such comparisons, buttheir traditional output may no longer be sufficient to evaluate theeffectiveness of health systems, and especially to explain geo-graphical differences in survival. In some countries, their role isalso under threat. Confidentiality constraints recently inhibitedthe collection of cancer registration data in the UK [90], and thelinkage of cancer registrations and deaths is currently illegal inEstonia [91]. Both activities are essential for internationally com-parable survival rates. Legal protection for cancer registrationacross Europe will be required.The mission of cancer registries should be reconsidered, and thepriority shifted from classical descriptive epidemiology and geo-graphical pathology toward more analytical monitoring ofprogress against cancer, including the probability of survival andcure, the burden of cancer prevalence, and the late effects oftherapy. Several European studies of this type have been reportedrecently [3, 36, 9294] and others are in progress. Many cancer–registries are developing closer relationships with cancer clini-cians and general practitioners, and some now systematicallycollect detailed clinical information that was collected eitherirregularly or not at all in the past. These developments willimprove the power of population-based cancer data to explain dif-ferences in cancer survival, and should enhance their relevance toclinical practice.European average survival rates are useful for comparativepurposes, but they should not become the goal for cancer controlprogrammes: the benchmark should always be the highest achiev-able survival rates.The aim of exploring geographic differences in cancer survivalis not to establish international league tables or to excite nationalrivalries, but to estimate the range of survival rates, and to identifyregions or countries in which survival could be improved.

Published
2003
Full Text
View/download PDF

22. Testicular cancer incidence in eight northern European countries: secular and recent trends

Author

Richiardi L, Bellocco R, Ho, Adami, Torrång A, Barlow L, Hakulinen T, Rahu M, Stengrevics A, Hans Storm, Tretli S, Kurtinaitis J, Je, Tyczynski, Akre O, Richiardi, L, Bellocco, R, Adami, H, Torrång, A, Barlow, L, Hakulinen, T, Rahu, M, Stengrevics, A, Storm, H, Tretli, S, Kurtinaitis, J, Tyczynski, J, and Akre, O

Subjects
Registrie, Adult, Male, Adolescent, Geography, Epidemiology, Incidence, Age Factors, Middle Aged, Epidemiologic Studie, Seminoma, Europe, Epidemiologic Studies, Oncology, Testicular Neoplasms, Humans, Age Factor, Registries, Testicular Neoplasm, Human
Abstract

Objective: Striking geographic variation and marked increasing secular trends characterize the incidence of testicular cancer. However, it is not known whether these patterns have attenuated in recent years and whether they are similar for seminomas and nonseminomas, the two main histologic groups of testicular cancer. Method: Cancer registry data, including 27,030 testicular cancer cases, were obtained from Denmark, Estonia, Finland, Latvia, Lithuania, Norway, Poland, and Sweden. Between 57 (Denmark) and 9 (Poland) years of registration were covered. Country-specific temporal trends were estimated, with focus on the last decade and seminomas and nonseminomas. Data from the Nordic countries were further analyzed using an age-period-cohort approach. Results: Age-standardized incidence rates increased annually by 2.6% to 4.9% during the study period, with marginal differences between seminomas and nonseminomas. In the last decade, the increasing trend attenuated only in Denmark (annual change, −0.3%; 95% confidence interval, −1.5 to 0.9). In 1995, the highest and the lowest age-standardized incidence rates (per 105) were 15.2 in Denmark and 2.1 in Lithuania. Incidence rates (i.e., for all cancers and for seminomas and nonseminomas, separately) depended chiefly on birth cohort rather than on calendar period of diagnosis (although both birth cohort and period determined the Danish incidence rates). Conclusions: Testicular cancer incidence is still increasing, with the exception of Denmark, and a large geographic difference exists. The increasing trend is mainly a birth cohort phenomenon also in recent cohorts. Temporal trends for seminomas and nonseminomas are similar, which suggests that they share important causal factors.

Published
2004

23. The Killer Fly Hunger Games : Target Size and Speed Predict Decision to Pursuit

Author

Wardill, T. J., Knowles, K., Barlow, L., Tapia, G., Nordström, Karin, Olberg, R. M., Gonzalez-Bellido, P. T., Wardill, T. J., Knowles, K., Barlow, L., Tapia, G., Nordström, Karin, Olberg, R. M., and Gonzalez-Bellido, P. T.

Abstract

Predatory animals have evolved to optimally detect their prey using exquisite sensory systems such as vision, olfaction and hearing. It may not be so surprising that vertebrates, with large central nervous systems, excel at predatory behaviors. More striking is the fact that many tiny insects, with their miniscule brains and scaled down nerve cords, are also ferocious, highly successful predators. For predation, it is important to determine whether a prey is suitable before initiating pursuit. This is paramount since pursuing a prey that is too large to capture, subdue or dispatch will generate a substantial metabolic cost (in the form of muscle output) without any chance of metabolic gain (in the form of food). In addition, during all pursuits, the predator breaks its potential camouflage and thus runs the risk of becoming prey itself. Many insects use their eyes to initially detect and subsequently pursue prey. Dragonflies, which are extremely efficient predators, therefore have huge eyes with relatively high spatial resolution that allow efficient prey size estimation before initiating pursuit. However, much smaller insects, such as killer flies, also visualize and successfully pursue prey. This is an impressive behavior since the small size of the killer fly naturally limits the neural capacity and also the spatial resolution provided by the compound eye. Despite this, we here show that killer flies efficiently pursue natural (Drosophila melanogaster) and artificial (beads) prey. The natural pursuits are initiated at a distance of 7.9 ± 2.9 cm, which we show is too far away to allow for distance estimation using binocular disparities. Moreover, we show that rather than estimating absolute prey size prior to launching the attack, as dragonflies do, killer flies attack with high probability when the ratio of the prey's subtended retinal velocity and retinal size is 0.37. We also show that killer flies will respond to a stimulus of an angular siz

Published
2015
Full Text
View/download PDF

24. The killer fly hunger games : target size and speed predict decision to pursuit

Author

Wardill, Trevor J., Knowles, K., Barlow, L., Tapia, G., Nordstrom, Karin, Olberg, R. M., Gonzalez-Bellido, Paloma T., Wardill, Trevor J., Knowles, K., Barlow, L., Tapia, G., Nordstrom, Karin, Olberg, R. M., and Gonzalez-Bellido, Paloma T.

Abstract

© The Author(s), 2015. This article is distributed under the terms of the Creative Commons Attribution License. The definitive version was published in Brain, Behavior and Evolution 86 (2015): 28-27, doi:10.1159/000435944., Predatory animals have evolved to optimally detect their prey using exquisite sensory systems such as vision, olfaction and hearing. It may not be so surprising that vertebrates, with large central nervous systems, excel at predatory behaviors. More striking is the fact that many tiny insects, with their miniscule brains and scaled down nerve cords, are also ferocious, highly successful predators. For predation, it is important to determine whether a prey is suitable before initiating pursuit. This is paramount since pursuing a prey that is too large to capture, subdue or dispatch will generate a substantial metabolic cost (in the form of muscle output) without any chance of metabolic gain (in the form of food). In addition, during all pursuits, the predator breaks its potential camouflage and thus runs the risk of becoming prey itself. Many insects use their eyes to initially detect and subsequently pursue prey. Dragonflies, which are extremely efficient predators, therefore have huge eyes with relatively high spatial resolution that allow efficient prey size estimation before initiating pursuit. However, much smaller insects, such as killer flies, also visualize and successfully pursue prey. This is an impressive behavior since the small size of the killer fly naturally limits the neural capacity and also the spatial resolution provided by the compound eye. Despite this, we here show that killer flies efficiently pursue natural (Drosophila melanogaster) and artificial (beads) prey. The natural pursuits are initiated at a distance of 7.9 ± 2.9 cm, which we show is too far away to allow for distance estimation using binocular disparities. Moreover, we show that rather than estimating absolute prey size prior to launching the attack, as dragonflies do, killer flies attack with high probability when the ratio of the prey's subtended retinal velocity and retinal size is 0.37. We also show that killer flies will respond to a stimulus of an angular size that is smaller t, This work was funded by the Air Force Office of Scientific Research (FA9550-10-0472 to R.M. Olberg and FA9550-15-1-0188 to P.T. Gonzalez-Bellido and K. Nordström), an Isaac Newton Trust/Wellcome Trust ISSF/University of Cambridge Joint Research Grant to Paloma T. Gonzalez-Bellido, a Biotechnology and Biological Sciences Research Council David Phillips Fellowship (BBSRC, BB/L024667/1) to Trevor J. Wardill, the Swedish Research Council (2012-4740) to Karin Nordström and a Shared Equipment Grant from the School of Biological Sciences (University of Cambridge).

Published
2015

25. Influence of morphology on survival for non-Hodgkin lymphoma in Europe and the United States

Author

Sant, Milena, Allemani, Claudia, De Angelis, Roberta, Carbone, Antonino, De SanJose, Silvia, Gianni, Alessandro M., Giraldo, Pilar, Marchesi, Francesca, Marcos-Gragera, Rafael, Martos-Jimenez, Carmen, Maynadie, Marc, Raphael, Martine, Berrino, Franco, Oberaigner, W., Storm, H. H., Aareleid, T., Jechova, M., Rousarova, M., Hakulinen, T., Hedelin, G., Tron, I., Le Gall, E., Launoy, G., MacE-Lesec'h, J., Faivre, J., Chaplain, G., Carli, P. -. M., Danzon, A., Tretarre, B., Colonna, M., Lacour, B., Raverdy, N., Berger, C., Freycon, F., Grosclaude, P., Estãve, J., Kaatsch, P., Ziegler, H., Holzel, D., Schubert Fritschle, G., Tryggvadottir, L., Berrino, F., Allemani, C., Baili, P., Ciccolallo, L., Crosignani, P., Gatta, G., Micheli, A., Sant, M., Ferretti, S., Contil, E., Ramazzotti, V., Vercelli, M., Quaglia, A., Pannelli, F., Federico, M., Artioli, M. E., Ponz De Leon, M., Benatti, P., De Lisi, V., Servente, L., Zanetti, R., Patriarca, S., Magnani, C., Pastore, G., Gafa, L., Tumino, R., Falcini, F., Budroni, M., Paci, E., Crocetti, E., Zambon, P., Guzzinati, S., Capocaccia, R., Carrani, E., De Angelis, R., Roazzi, P., Santaquilani, M., Tavilla, A., Valente, F., Verdecchia, A., Dalmas, M., Langmark, F., Andersen, A., Rachtan, J., Bielska-Lasota, M., Wronkowski, Z., Plesko, I., Obsitnikova, A., Pompe-Kirn, V., Izarzugaza, I., Martinez-Garcia, C., Garau, I., Navarro, C., Chirlaque, M. D., Ardanaz, E., Moreno, C., Galceran, J., Torrella, A., Peris-Bonet, R., Barlow, L., Moller, T., Jundt, G., Lutz, J. M., Usel, M., Coebergh, J. W. W., Van Der Does-Van Den Berg, A., Visser, O., Godward, S., Coleman, M. P., Williams, E. M. I., Forman, D., Quinn, M. J., Roche, M., Edwards, S., Stiller, C., Verne, J., Mã¸ller, H., Bell, J., Botha, J. L., Lawrence, G., Black, R., Steward, J. A., Department of Preventive and Predictive Medicine, Unit of Etiological Epidemiology and Prevention, Istituto Nazionale per lo Studio e la Cura dei Tumori, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Hospital Miguel Servet, Registre des hémopathies malignes de Côte d'Or, Laboratoire d'Hématologie, Université Paris-Sud - Paris 11 ( UP11 ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Bicêtre, Department of Preventive & Predictive Medicine, Fondazione IRCCS-Istituto Nazionale dei Tumori, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Hospital Universitario Miguel Servet, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)

Subjects
Oncology, Cancer Research, Survival, Lymphoma, MESH: Registries, MESH : Age Distribution, MESH : Aged, MESH : Child, Preschool, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, MESH: Aged, 80 and over, MESH: Lymphoma, Non-Hodgkin, MESH : Child, MESH: Child, hemic and lymphatic diseases, 80 and over, Medicine, Registries, Child, Aged, 80 and over, MESH: Aged, MESH: Middle Aged, MESH : Prognosis, Relative survival, Lymphoma, Non-Hodgkin, EUROCARE, Non-Hodgkin's lymphoma, Population cancer registries, US SEER, Adolescent, Adult, Age Distribution, Aged, Child, Preschool, Europe, Feasibility Studies, Humans, Infant, Middle Aged, Prognosis, United States, Absolute risk reduction, MESH : Infant, MESH : Adult, MESH: Infant, 3. Good health, 030220 oncology & carcinogenesis, morphology - survival - non Hodgkin lymphoma - Europe - US, epidemiology, medicine.medical_specialty, MESH : United States, MESH : Feasibility Studies, MESH : Europe, Socio-culturale, Non-Hodgkin, [SDV.CAN]Life Sciences [q-bio]/Cancer, survival, MESH: Prognosis, cancer, 03 medical and health sciences, Internal medicine, MESH : Adolescent, MESH: United States, MESH : Lymphoma, Non-Hodgkin, MESH : Middle Aged, Preschool, MESH : Aged, 80 and over, MESH: Age Distribution, MESH: Adolescent, MESH: Humans, business.industry, MESH: Child, Preschool, MESH : Humans, Cancer, MESH: Adult, medicine.disease, Confidence interval, Cancer registry, Hodgkin lymphoma, MESH: Europe, business, MESH: Feasibility Studies, MESH : Registries, 030215 immunology
Abstract

International audience; We explored the influence of morphology on geographic differences in 5-year survival for non-Hodgkin lymphoma (NHL) diagnosed in 1990-1994 and followed for 5years: 16,955 cases from 27 EUROCARE-3 cancer registries, and 22,713 cases from 9 US SEER registries. Overall 5-year relative survival was 56.1% in EUROCARE west, 47.1% in EUROCARE east and 56.3% in SEER. Relative excess risk (RER) of death was 1.05 (95% confidence interval (CI) 1.01-1.10) in EUROCARE west, 1.52 (95% CI 1.44-1.60) in EUROCARE east (SEER reference). Excess risk of death was significantly above reference (diffuse B lymphoma) for Burkitt's and NOS lymphoma; not different for lymphoblastic and other T-cell; significantly below reference (in the order of decreasing relative excess risk) for NHL NOS, mantle cell/centrocytic, lymphoplasmacytic, follicular, small lymphocytic/chronic lymphocytic leukaemia, other specified NHL and cutaneous morphologies. Interpretation of marked variation in survival with morphology is complicated by classification inconsistencies. The completeness and standardisation of cancer registry morphology data needs to be improved.

Published
2008
Full Text
View/download PDF

26. Trends in cervical cancer survival in Europe, 1983-1994: a population-based study

Author

Bielska-Lasota, M., Inghelmann, R., van de Poll-Franse, L., Capocaccia, R., Storm, H. H., Aareleid, T., Jechova, M., Rousarova, M., Hakulinen, T., Hedelin, G., Tron, I., Le Gall, E., Launoy, G., Mace-Lesec'h, J., Faivre, J., Chaplain, G., Carli, P. -M., Danzon, A., Tretarre, B., Colonna, M., Lacour, B., Raverdy, N., Berger, C., Freycon, B., Grosclaude, P., Esteve, J., Kaatsch, P., Ziegler, H., Holzel, D., Schubert Fritschle, G., Tryggvadottir, L., Berrino, F., Allemani, C., Baili, P., Ciccolallo, L., Crosignani, P., Gatta, G., Micheli, A., Sant, M., Taussig, E., Sowe, S., Ferretti, S., Conti, E., Vercelli, M., Quaglia, A., Pannelli, F., Federico, M., Artioli, M. E., Ponz De Leon, M., Benatti, P., De Lisi, V., Servente, L., Zanetti, R., Patriarca, S., Magnani, C., Pastore, G., Gafa, L., Tumino, R., Falcini, F., Budroni, M., Paci, E., Crocetti, E., Zambon, P., Guzzinati, S., Carrani, E., De Angelis, R., Roazzi, P., Santaquilani, M., Tavilla, A., Valente, F., Verdecchia, A., Dalmas, M., Langmark, F., Andersen, A., Pinheiro, P., Rachtan, J., Wronkowski, Z., Zwierko, M., Plesko, I., Obsitnikova, A., Pompe-Kirn, V., Primic-Zakelj, M., Izarzugaza, I., Martinez-Garcia, C., Garau, I., Navarro, C., Chirlaque, M. D., Ardanaz, E., Moreno, C., Galceran, J., Torrella, A., Peris-Bonet, R., Barlow, L., Moller, T., Jundt, G., Lutz, J. M., Bouchardy, C., Coebergh, J. W. W., van der Does-van den Berg, A., Visser, O., Godward, S., Coleman, M. P., Williams, E. M. I., Forman, D., Quinn, M. J., Roche, M., Edwards, S., Stiller, C., Verne, J., Moller, H., Bell, J., Botha, H., Lawrence, G., Black, R., Steward, J. A., Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)

Subjects
MESH: Registries, MESH : Mortality, MESH : Aged, Uterine Cervical Neoplasms, Disease, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, MESH: Aged, 80 and over, 0302 clinical medicine, MESH : Female, Registries, MESH: Aged, Cervical cancer, Aged, 80 and over, 0303 health sciences, education.field_of_study, MESH: Middle Aged, MESH : Prognosis, Relative survival, Absolute risk reduction, Obstetrics and Gynecology, Middle Aged, MESH : Adult, Prognosis, MESH : Survival Rate, 3. Good health, MESH: Uterine Cervical Neoplasms, Europe, Survival Rate, Oncology, 030220 oncology & carcinogenesis, Adenocarcinoma, Female, Adult, medicine.medical_specialty, MESH: Survival Rate, Adolescent, Population, MESH : Uterine Cervical Neoplasms, MESH : Europe, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH: Prognosis, Trends - cervical cancer - survival, 03 medical and health sciences, MESH : Adolescent, medicine, Humans, MESH : Middle Aged, Mortality, education, MESH : Aged, 80 and over, Survival rate, 030304 developmental biology, Aged, MESH: Adolescent, Gynecology, MESH: Humans, MESH: Mortality, business.industry, MESH : Humans, Cancer, MESH: Adult, Population-based study, Survival, Trends, medicine.disease, MESH: Europe, business, MESH: Female, MESH : Registries, Demography
Abstract

International audience; OBJECTIVE: To evaluate trends in survival from cervical cancer in Europe and in European countries participating in the EUROCARE study as a function of age, morphology and stage at diagnosis. METHODS: Relative survival and relative excess risk of death within 5 years of diagnosis, as a function of age, morphology and stage, among 73,022 women aged 15-99 years diagnosed during 1983-1994 and followed up to 1999 in each of 18 European countries participating in the EUROCARE study, using data from 34 population-based cancer registries. RESULTS: Overall five-year relative survival was 62%, rising by 2% during the period 1983-1994. The highest survival occurred in Northern and Western Europe and the lowest in Central Europe. Survival falls with age at diagnosis, but mainly for localised disease. Survival is higher for adenocarcinoma in younger women, but higher for squamous cell carcinoma in older women. The proportions of younger women, localised cancer and adenocarcinoma all increased. The main improvements in survival were for women under 65, and for metastatic disease. CONCLUSIONS: Survival in Europe has improved slowly but steadily, but the trend is not geographically uniform. Central European countries and the UK saw little or no improvement, and survival in those countries remains the lowest among participating countries in Europe. Further reduction of cervical cancer mortality in Europe may be expected from expansion of screening, and improvement in the treatment of older women, and of metastatic disease.

Published
2007
Full Text
View/download PDF

27. Survival from rare cancer in adults: a population-based study

Author

Gatta, G., Ciccolallo, L., Kunkler, I., Capocaccia, R., Berrino, F., Coleman, M. P., De Angelis, R., Faivre, J., Lutz, J. M., Martinez, C., Möller, T., Sankila, R., Oberaigner, W., Storm, H. H., Aareleid, T., Jechova, M., Rousarova, M., Hakulinen, T., Hédelin, G., Tron, I., Le Gall, E., Launoy, G., Macé Lesec'h, J., Chaplain, G., Carli, P. M., Danzon, A., Tretarre, B., Colonna, M., Lacour, B., Raverdy, N., Berger, C., Freycon, B., Grosclaude, P., Estève, J., Kaatsch, P., Ziegler, H., Hölzel, D., Schubert Fritschle, G., Tryggvadottir, L., Allemani, C., Baili, P., Crosignani, P., Micheli, A., Sant, M., Taussig, E., Sowe, S., Ferretti, S., Conti, E., Vercelli, M., Quaglia, A., Pannelli, F., Federico, Massimo, Artioli, M. E., PONZ DE LEON, Maurizio, Benatti, Piero, De Lisi, V., Servente, L., Zanetti, R., Patriarca, S., Magnani, C., Pastore, G., Gafa, L., Tumino, R., Falcini, F., Budroni, M., Paci, E., Crocetti, E., Zambon, P., Guzzinati, S., Carrani, E., Roazzi, P., Santaquilani, M., Tavilla, A., Valente, F., Verdecchia, A., Dalmas, M., Langmark, F., Andersen, A., Pinheiro, P., Rachtan, J., Bielska Lasota, M., Wronkowski, Z., Zwierko, M., Pleško, I., Obsitníkováa, A., Pompe Kirn, V., Primic Zakelj, M., Izarzugaza, I., Martinez Garcia, C., Garau, I., Navarro, C., Chirlaque, M. D., Ardanaz, E., Moreno, C., Galceran, J., Torrella, A., Peris Bonet, R., Barlow, L., Jundt, G., Bouchardy, C., Coebergh, J. W. W., van der Does van den Berg, A., Visser, O., Godward, S., Williams, E. M. I., Forman, D., Quinn, M. J., Roche, M., Edwards, S., Stiller, C., Verne, J., Møller, H., Bell, J., Botha, H., Lawrence, G., Black, R., Steward, J. A., Evaluative Epidemiology Unit, Fondazione IRCCS, Department of Preventive & Predictive Medicine, Fondazione IRCCS-Istituto Nazionale dei Tumori, Registre Bourguignon des Cancers Digestifs, Lipides - Nutrition - Cancer (U866) ( LNC ), Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon ( ENSBANA ) -Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon ( ENSBANA ) -Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Registre Genevois des Tumeurs, CHU Genève, Service of Preventive Medicine, Hospital Clínico San Carlos, Madrid, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Lipides - Nutrition - Cancer (U866) (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA)-Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA)-Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)

Subjects
Male, Oncology, MESH : Risk, MESH : Aged, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, Neoplasms, Angiosarcoma, MESH: Neoplasms, MESH : Female, MESH: Quality of Health Care, MESH: Aged, 0303 health sciences, MESH: Risk, MESH: Middle Aged, Relative survival, MESH : Quality of Health Care, Rare cancer survival, population-based cancer study, international comparison, Middle Aged, MESH : Adult, 3. Good health, Europe, 030220 oncology & carcinogenesis, MESH: Survival Analysis, MESH : Rare Diseases, Female, Sarcoma, Adult, Risk, MESH: Rare Diseases, medicine.medical_specialty, Adolescent, MESH : Male, MESH : Europe, [SDV.CAN]Life Sciences [q-bio]/Cancer, 03 medical and health sciences, Rare Diseases, Internal medicine, MESH : Adolescent, medicine, Carcinoma, Humans, MESH : Middle Aged, Testicular cancer, Survival analysis, Aged, Quality of Health Care, 030304 developmental biology, MESH: Adolescent, MESH: Humans, Uterine sarcoma, business.industry, MESH : Humans, Cancer, MESH: Adult, medicine.disease, Survival Analysis, MESH : Neoplasms, MESH: Male, MESH: Europe, MESH : Survival Analysis, business, MESH: Female
Abstract

International audience; BACKGROUND: Rare cancers are a challenge to clinical practice, and treatment experience, even in major cancer centres to which rare cancers are usually referred, is often limited. We aimed to study the epidemiology of rare cancers in a large population of several countries. METHODS: We analysed survival by age, sex, subsite, and morphology in 57,144 adults with 14 selected rare cancers diagnosed 1983-94. Variations in survival over time and between European regions were also assessed for variations in quality of care. We also estimated the adjusted relative excess risk of death for every rare cancer. FINDINGS: Overall 5-year relative survival was good (ie, >65%) for placental choriocarcinoma (85.4% [95% CI 81.4-89.5]), thyroid medullary carcinoma (72.4% [69.2-75.5]), ovarian germ-cell cancer (73.0% [70.0-76.0]), lung carcinoid (70.1% [67.3-72.9]), and cervical adenocarcinoma (65.5% [64.3-66.6]); intermediate (ie, 35-65%) for testicular cancer at age 65 years or older (64.0% [59.3-68.7]), sarcoma of extremities (60.0% [58.9-61.2]), digestive-system endocrine cancers (55.6% [54.9-56.3]), anal squamous-cell carcinoma (53.1% [51.5-54.8]), and uterine sarcoma (43.5% [42.0-44.9]); low for carcinoma of adrenal-gland cortex (32.7% [28.3-37.2]) and bladder squamous-cell carcinoma (20.4% [18.8-22.0]); and poor for angiosarcoma of liver (6.4% [1.8-11.0]) and mesothelioma (4.7% [4.3-5.2]). Survival was usually better for women than men and poor in those aged 75 years or older. Survival significantly improved over time for ovarian germ-cell cancer, sarcomas of extremities, digestive-system endocrine tumours, anal squamous-cell carcinoma, and angiosarcoma of liver. Survival in northern Europe was higher than in the other geographic groupings for most cancers. INTERPRETATION: Because effective treatments are available for several of the rare cancers we assessed, further research is needed to ascertain why survival is lower in some European countries than in others, particularly in older patients. Audit of best practice for rare cancers with treatment protocols would be useful.

Published
2006
Full Text
View/download PDF

28. The EUROCARE-3 database: methodology of data collection, standardisation, quality control and statistical analysis

Author

Capocaccia, R., Gatta, G., Roazzi, P., Carrani, E., Santaquilani, M., De Angelis, R., Tavilla, A., Oberaigner, W., Jechova, M., Rousarova, M., Storm, H. H., Aareleid, T., Hakulinen, T., Hédelin, G., Tron, I., Le Gall, E., Launoy, G., Macé Lesech, J., Faivre, J. n. Chaplain G., Carli, P. M., Danzon, A., Tretarre, B., Colonna, M., Lacour, B., Raverdy, N., Berger, C., Freycon, F., Grosclaude, P., Estève, J., Kaatch, P., Ziegler, H., Hölzel, D., Fritschle, G. S., Tryggvadottir, L., Berrino, F., Allemani, C., Baili, P., Ciccolallo, L., Micheli, A., Sant, M., Taussig, E., Hartley, S., Valente, F., Verdecchia, A., Ferretti, S., Crosignani, P., Tagliabue, G., Conti, E., Vercelli, M., Pannelli, F., Vitarelli, S., Mosciatti, P., Federico, Massimo, Artioli, M. E., PONZ DE LEON, Maurizio, Benatti, Piero, De Lisi, V., Serventi, L., Zanetti, R., Patriarca, S., Magnani, C., Pastore, G., Gafà, L., Tumino, R., Falcini, F., Budroni, M., Paci, E., Crocetti, E., Zambon, P., Guzzinati, S., Dalmas, M., Langmark, F., Andersen, A., Rachtan, J., Bielska Lasota, M., Wronkowski, Z., Zwierko, M., Pinheiro, P. S., Pleško, I., Obsitníková, A., Pompe Kim, V., Izarzugaza, I., Martinez Garcia, C., Garau, I., Navarro, C., Chirlaque, M. D., Ardanaz, E., Moreno, C., Galceran, J., Torrella, A., Perisbonet, R., Barlow, L., Möller, T., Jundt, G., Lutz, J. M., Usel, M., Coebergh, J. W. W., Van Der Does Van Den, A., Visser, O., Godward, S., Coleman, M. P., Williams, E. M. I., Forman, D., Quinn, M. J., Roche, M., Edwards, S., Stiller, C., Verne, J., Møller, H., Bell, J., Botha, J. L., Lawrence, G., Black, R., Brewster, D., and Steward, J. A.

Subjects
Adult, Male, Quality Control, computer.software_genre, Stomach Neoplasms, Neoplasms, Autopsy Only, Cancer survival, Data quality, Population-based cancer registries, standardisation - quality control - statistical analysis, medicine, Humans, Statistical analysis, Registries, Medical diagnosis, Stage (cooking), Child, cancer survival, methodology - data collection, Data collection, Database, Relative survival, business.industry, Data Collection, Age Factors, Cancer, Hematology, medicine.disease, Survival Analysis, Europe, Survival Rate, Databases as Topic, Oncology, Data quality, Female, Colorectal Neoplasms, business, computer
Abstract

The EUROCARE database contains data on 6.5 million cancer patients diagnosed from 1978 to 1994 in populations covered by 67 cancer registries in 22 European countries. The quality-checked entries specify age, sex, diagnosis date, cancer site, morphology, microscopic confirmation and vital status, as well as containing broad indicators of stage. For EUROCARE-3, which refers to diagnoses from 1990 to 1994, 3389 cases with major data problems and 142,525 second or subsequent cancers were removed, leaving more than 2 million cases for analysis. From these data, observed and relative survival for each cancer site and country were calculated at 1, 3 and 5 years from diagnosis. Overall European survival for each cancer site and for all cancers combined were calculated combining country-specific survival figures. Overall, 1.1% of cases were lost to follow-up, 4.2% were known from death certificates only and 1.2% were known at autopsy only. The percentage of microscopically confirmed cases varied with cancer site and country, and was always higher in northern European countries. Comparison of quality indicators for the EUROCARE-3 database with earlier EUROCARE databases indicates that data quality and standardisation have improved.

Published
2003

29. Combining 'Paddock models' and geographical information systems can be a powerful tool in catchment planning

Author

Rattray, D. J., Silburn, D. M., Owens, J., Barlow, L., Rattray, D. J., Silburn, D. M., Owens, J., and Barlow, L.

Abstract

A gap exists in catchment modelling approaches that can be filled by bio-physical models. We have run bio-physical models for a catchment to describe the water balance and erosion due to the interactions between the soil, vegetation, management and climate for each paddock. The paddock scale results were used in two ways. Firstly, the water balance components and erosion rates were presented as a map and used as a risk assessment tool. Secondly, the runoff, drainage and erosion from each paddock were added together to predict whole catchment stream flow, groundwater recharge and sediment export rate respectively. Stream flow and groundwater recharge were also used as inputs into the 2CSalt model to predict salt export from the sub-catchment. Monthly runoff for the catchment was well described by the models (R2= 0.9). Sediment export rates were not easily tested due to limited observations but bio-physical modelling has proved useful for catchment planners to prioritise erosion management. We see the advantage bio-physical models provide over other methods, is the ability to assess a proposed land use system at the paddock scale (a manageable land unit), while also being able to assess the impact of paddock scale action on the catchment. © HWRS 2006.

Published
2006

31. Testicular cancer incidence in eight northern European countries: secular and recent trends

Author

Richiardi, L, Bellocco, R, Adami, H, Torrång, A, Barlow, L, Hakulinen, T, Rahu, M, Stengrevics, A, Storm, H, Tretli, S, Kurtinaitis, J, Tyczynski, J, Akre, O, Akre, O., BELLOCCO, RINO, Richiardi, L, Bellocco, R, Adami, H, Torrång, A, Barlow, L, Hakulinen, T, Rahu, M, Stengrevics, A, Storm, H, Tretli, S, Kurtinaitis, J, Tyczynski, J, Akre, O, Akre, O., and BELLOCCO, RINO

Abstract

Striking geographic variation and marked increasing secular trends characterize the incidence of testicular cancer. However, it is not known whether these patterns have attenuated in recent years and whether they are similar for seminomas and nonseminomas, the two main histologic groups of testicular cancer.

Published
2004

44. Work-related cancer in the Nordic countries.

Author

Andersen, A., Barlow, L., Engeland, A., Kjærheim, K., Lynge, Elsebeth, Pukkala, E., Andersen, A., Barlow, L., Engeland, A., Kjærheim, K., Lynge, Elsebeth, and Pukkala, E.

Published
1999

45. Recent trends in breast cancer incidence in Sweden

Author

Persson, I, Bergstrom, R, Barlow, L, Adami, HO, Persson, I, Bergstrom, R, Barlow, L, and Adami, HO

Abstract

Breast cancer incidence in Sweden during the period 1984-93 shows no clear trend in women aged below 40 years but a transient increase at ages 50-69 years, probably as a result of mammography screening. Our data give no indication that use of oral contrac, Addresses: Persson I, Karolinska Inst, Dept Med Epidemiol, S-17177 Stockholm, Sweden. Karolinska Inst, Dept Med Epidemiol, S-17177 Stockholm, Sweden. Uppsala Univ, Dept Stat, Uppsala, Sweden. Natl Board Hlth & Welf, Ctr Epidemiol, S-10630 Stockholm, Swede

Published
1998

46. European health systems and cancer care

Author

Micheli, A., primary, Coebergh, J.W., additional, Mugno, E., additional, Massimiliani, E., additional, Sant, M., additional, Oberaigner, W., additional, Holub, J., additional, Storm, H.H., additional, Forman, D., additional, Quinn, M., additional, Aareleid, T., additional, Sankila, R., additional, Hakulinen, T., additional, Faivre, J., additional, Ziegler, H., additional, Tryggvadòttir, L., additional, Zanetti, R., additional, Dalmas, M., additional, Visser, O., additional, Langmark, F., additional, Bielska-Lasota, M., additional, Wronkowski, Z., additional, Pinheiro, P.S., additional, Brewster, D.H., additional, Pleško, I., additional, Pompe-Kirn, V., additional, Martinez-Garcia, C., additional, Barlow, L., additional, Möller, T., additional, Lutz, J.M., additional, André, M., additional, and Steward, J.A., additional

Published
2003
Full Text
View/download PDF

48. Risk of cancer and Exposure to gasoline vapours

Author

Lynge, E, Andersen, A, Nilsson, R, Barlow, L, Pukkala, E, Norlinder, R, Bofetta, P, Grandjean, P, Heikkila, P, Horte, L-G, Jakobsson, R, Lundberg, I, Moen, B, Partanen, T, Riise, T, Lynge, E, Andersen, A, Nilsson, R, Barlow, L, Pukkala, E, Norlinder, R, Bofetta, P, Grandjean, P, Heikkila, P, Horte, L-G, Jakobsson, R, Lundberg, I, Moen, B, Partanen, T, and Riise, T

Published
1997

50. Chapter 3. Major Health Problems

Author

Persson, G., primary, Barlow, L., additional, Karlsson, A., additional, Rosen, M., additional, Stefansson, C.-G., additional, Theorell, T., additional, Tull, P., additional, and Aberg, A., additional

Published
2001
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results